| Ytd | ||
| 1y |
| Open | 8.05 | Prev Close | 8.05 | Low | 8.05 | High | 8.05 | Mkt Cap | 375.71M |
| Vol | 5.51M | Avg Vol | 1.65M | EPS | -2.10 | P/E | -3.83 | Forward P/E | -0.87 |
| Beta | 3.33 | Short Ratio | 5.31 | Inst. Own | 80.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 7.97 | 200-d Avg | 3.80 | 1yr Est | 16.19 |
VIGL News
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
The mean of analysts' price targets for Vigil Neuroscience (VIGL) points to a 26.1% upside in the st
NEW YORK , June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigat
The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vi
PHILADELPHIA , June 4, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is inv
WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clini
After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pic
NYC, May 24, 2025 (GLOBE NEWSWIRE) -- NEW YORK, May 24, 2025 / GlobeNewswire/ -- Class Action Attorn
The consensus price target hints at an 86.7% upside potential for Vigil Neuroscience (VIGL). While e
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Vigil (Nasdaq: VIGL) for possible breach
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in ca
Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company,
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALS
- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG
Vigil Neuroscience (VIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab
– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of
WATERTOWN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clin
Shares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance.
On Monday, 147 stocks hit new 52-week lows.
Gainers